GSK buys back 482k shares at 1,402p VWAP; treasury now 5.52 %

Q: How many GSK (GSK) shares were repurchased on 27 June 2025?

482,114 ordinary shares were bought back.

Q: What price did GSK pay for its share buy-back on 27 June 2025?

Prices ranged from 1,395.50 p to 1,410.50 p with a VWAP of 1,402.45 p.

Q: How many shares has GSK repurchased since 4 June 2025?

The company has bought back 7,554,354 shares in total under the current mandate.

Q: What proportion of GSK鈥檚 voting rights are now held in treasury?

Treasury shares represent 5.52 % of total voting rights.

[Form 4] Byrna Technologies, Inc. Insider Trading Activity

Filing Impact

(Low)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

GSK plc filed a Form 6-K reporting routine activity under its June 2025 share buy-back mandate. Acting through its broker Merrill Lynch International, the company repurchased 482,114 ordinary shares (nominal value 31 录 p) on 27 June 2025.

Key trade metrics reported for the London Stock Exchange (XLON):

Price range: 1,395.50 p 鈥� 1,410.50 p
Volume-weighted average price (VWAP): 1,402.45 p

The shares will be held in treasury. Since launching the non-discretionary agreement with the broker on 4 June 2025, GSK has bought back a cumulative 7,554,354 shares.

Post-transaction, GSK鈥檚 capital structure is as follows:

Treasury shares: 225,688,737
Shares outstanding (excluding treasury): 4,089,681,462
Total voting rights in issue: 4,089,681,462
Treasury shares as a percentage of voting rights: 5.52 %

The filing also provides a full schedule of individual XLON trades and confirms no purchases occurred on CBOE venues (CHIX or BATE) on the reporting date.

Positive

Continuation of share buy-back programme demonstrates ongoing capital return policy.
Treasury share percentage of 5.52 % offers management flexibility for future capital actions.

Negative

None.

Insights

TL;DR: Modest continuation of existing buy-back; supportive but not material.

The purchase of 0.01 % of shares outstanding (482k/4.09 bn) is a standard daily execution under GSK鈥檚 June programme. While buy-backs can enhance EPS and signal management confidence, the scale here is immaterial to valuation. Cumulative repurchases since 4 June total 0.18 % of share capital鈥攈elpful but unlikely to influence earnings forecasts or leverage metrics. No new authorisation or change in strategy is disclosed, so investor impact is limited to marginal reduction in float and steady technical support for the share price.

TL;DR: Routine treasury transaction; neutral for portfolio positioning.

Daily buy-back executions improve liquidity absorption but do not alter our weighting. The 5.52 % treasury position remains below UK limits and provides flexibility for option settlements or future cancellations. Absence of earnings guidance, capital allocation changes, or enlargement of the buy-back cap means no adjustment to risk models is warranted. Event classified as not impactful.

06/30/2025 - 06:45 AM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KEARNES LAURILEE

(Last)

(First)

(Middle)

100 BURTT ROAD, SUITE 115

(Street)

ANDOVER

01810

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Byrna Technologies Inc. [ BYRN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
06/19/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/19/2025		M⁽³⁾		5,000	A	⁽¹⁾	8,500	D
Common Stock	06/19/2025		F⁽²⁾		1,426	D	$29.82	7,074	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Unit	⁽¹⁾	06/19/2025		M			5,000	⁽³⁾	⁽³⁾	Common Stock	5,000	⁽¹⁾	20,000	D

Explanation of Responses:

1. Each restricted stock unit represents the right to receive, at settlement, one share of common stock. This transaction represents the settlement of 5,000 restricted stock units in shares of common stock upon vesting.

2. In accordance with the terms of the Company's Amended and Restated 2020 Incentive Equity Plan and the Restricted Stock Unit Award Agreement, the Reporting Owner forfeited her rights to 1,426 shares of common stock that otherwise was due to her as part of the RSU settlement to cover the Reporting Owner's withholding tax obligations arising from settlement of vested restricted stock units. There was no market transaction in connection with this forfeiture. Reporting owner was issued the net number of shares (3,574) reflecting the 5,000 rsus settlement net of the 1,426 shares withhdeld for taxes calculated at the prior trading day's closing price of $29.82.

3. These restricted stock units vested and were settled on 6/19/25.

	/s/ Lisa Klein Wager by Power of Attorney	06/30/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

How many GSK (GSK) shares were repurchased on 27 June 2025?

482,114 ordinary shares were bought back.

What price did GSK pay for its share buy-back on 27 June 2025?

Prices ranged from 1,395.50 p to 1,410.50 p with a VWAP of 1,402.45 p.

How many shares has GSK repurchased since 4 June 2025?

The company has bought back 7,554,354 shares in total under the current mandate.

What is GSK鈥檚 current number of shares outstanding?

After the transaction, shares outstanding (excluding treasury) total 4,089,681,462.

What proportion of GSK鈥檚 voting rights are now held in treasury?

Treasury shares represent 5.52 % of total voting rights.

Will this filing affect GSK鈥檚 earnings per share (EPS)?

The repurchased amount is <1 bp of shares outstanding, so any EPS effect will be immaterial.

AG真人官方

[Form 4] Byrna Technologies, Inc. Insider Trading Activity

Insights

FAQ

How many GSK (GSK) shares were repurchased on 27 June 2025?

What price did GSK pay for its share buy-back on 27 June 2025?

How many shares has GSK repurchased since 4 June 2025?

What is GSK鈥檚 current number of shares outstanding?

What proportion of GSK鈥檚 voting rights are now held in treasury?

Will this filing affect GSK鈥檚 earnings per share (EPS)?

NASDAQ:BYRN

BYRN Rankings

BYRN Latest News

BYRN Latest SEC Filings

BYRN Stock Data

AG真人官方

Trending News

[Form 4] Byrna Technologies, Inc. Insider Trading Activity

Insights

Equity Research Analyst neutral

Portfolio Manager neutral

FAQ

How many GSK (GSK) shares were repurchased on 27 June 2025?

What price did GSK pay for its share buy-back on 27 June 2025?

How many shares has GSK repurchased since 4 June 2025?

What is GSK鈥檚 current number of shares outstanding?

What proportion of GSK鈥檚 voting rights are now held in treasury?

Will this filing affect GSK鈥檚 earnings per share (EPS)?

NASDAQ:BYRN

BYRN Rankings

BYRN Latest News

BYRN Latest SEC Filings

BYRN Stock Data